Pharmaceuticals and brain health… biotech industry?
McDonald explains, “We are improving on first-generation psychedelic compounds like psilocybin. Unlike other products on the market, we are developing next-generation superior molecules that are engineered to target specific serotonin receptors. Our drugs will replace psilocybin in dealing with issues like depression. This leads to fewer side effects while improving safety and efficacy.” Biotech companies…
Recent Comments